“No evidence of disease activity”: Is it an aspirational therapeutic goal in multiple sclerosis?
Author:
Publisher
Elsevier BV
Subject
Neurology (clinical),Neurology,General Medicine
Reference85 articles.
1. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial;Arnold;BMC Neurol,2017
2. Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis;Arnold;Ther. Adv. Neurol. Disord.,2018
3. Addressing the regulatory and scientific challenges in multiple sclerosis–a statement from the EU regulators;Balabanov;Mult. Scler.,2014
4. The clinico-radiological paradox in multiple sclerosis revisited;Barkhof;Curr. Opin. Neurol.,2002
5. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis;Barro;Brain,2018
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Prevalence of 2-year “No evidence of disease activity” (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study;Multiple Sclerosis and Related Disorders;2023-11
2. Progression events defined by home-based assessment of motor function in multiple sclerosis: protocol of a prospective study;Frontiers in Neurology;2023-10-10
3. Predictive value of brain atrophy, serum biomarkers and information processing speed for early disease progression in multiple sclerosis;Frontiers in Neurology;2023-07-25
4. Multiple Sclerosis in Korea: A Hospital-Based, Multicenter, Epidemiological Study;Journal of Multiple Sclerosis and Neuroimmunology;2023-06-30
5. VEP Score of a Left Eye Had Predictive Values for Achieving NEDA-3 over Ten Years in Patients with Multiple Sclerosis;Sensors;2022-11-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3